AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 54 min read$RVTY

Why Revvity (RVTY) Stock Is Up Today

Revvity (NYSE: RVTY) shares rose about 3% after the company reported Q2 2026 adjusted EPS of $1.41 versus $1.21 expected, and revenue of $729.68 million versus $703.39 million. Revvity lifted full-year guidance to 4% to 5% organic growth and EPS of $5.30 to $5.40. Stifel raised its target to $110 and Bernstein to $120.

Original reporting
financialcontent.com
Published Aug 5, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Why Revvity (RVTY) Stock Is Up Today — source image
Source · financialcontent.com
Decision brief

The 30-second read

$RVTYBullishMed
01

Why it matters

Q2 beat plus raised full-year organic growth and EPS range is a direct catalyst for repricing, reflected in the afternoon +3.1% move and subsequent cooling to +2.6%.

02

Market read

This is a same-day earnings and guidance catalyst for RVTY, with analyst target increases reinforcing the positive market reaction.

03

What to watch

The article does not quantify margin, cash flow, or segment profitability; traders may reprice on quality of earnings rather than top-line/organic growth alone.

Relevance 8/10Novelty 8/10Timing: after-hours/afternoon session reaction to Q2 results and raised FY guidance (Aug 5, 2026)

Background

Revvity is a life sciences company with Diagnostics and Life Science segments; prior quarter guidance was described as cautious in the article’s recap.

Company-level read

Ticker impact

$RVTYBullishMedium confidence
Context

Revvity reported Q2 2026 adjusted EPS of $1.41 and revenue of $729.68M, beating estimates and lifting full-year guidance.

Expected impact

Bullish bias for the next few sessions, with potential for profit-taking given the stock’s proximity to the 52-week high.

Evidence & confidence

The article cites a same-day +3.1% move tied directly to the EPS/revenue beat and raised FY organic growth and EPS range, plus analyst target increases.

Market effects

Sector

Positive read-through for life sciences tools and diagnostics demand expectations, though the article is single-company focused.

Regional

No specific regional effects mentioned beyond US-listed trading reaction.

Global

No explicit global macro or international regulatory drivers cited.

Counterpoint

What could challenge this read

The stock’s move may fade if investors focus on the magnitude of the raised guidance versus prior expectations, especially with shares near the 52-week high.

Key entities

  • company
    Revvity

    Reported Q2 2026 adjusted EPS of $1.41 and revenue of $729.68M, and raised full-year guidance to 4-5% organic growth and EPS $5.30-$5.40.

  • analyst_firm
    Stifel

    Raised its price target to $110 from $100 after the results.

  • analyst_firm
    Bernstein

    Increased its target to $120 from $115 following the results.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 1
$RVTYMed

RBC Capital initiates Revvity stock with Sector Perform rating

RBC Capital initiated coverage on Revvity Inc. (NYSE:RVTY) with a Sector Perform rating and a $135 price target. The stock trades near its 52-week high after a 31% surge over six months. RBC cited durable franchises but noted structural challenges to growth. Revvity's P/E ratio is 61, and it is considered overvalued. The company reported Q2 earnings and revenue above expectations, driven by organic growth and AI demand. Stifel raised its price target to $110 but maintained a Hold rating.

investing.com2 min
AUG 31
$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min
AUG 11
$RVTYHighAI 9/10

Revvity (RVTY) Q2 2026 Earnings Call Transcript

Revvity (RVTY) reported Q2 2026 pro forma revenue of $711 million, up 3% organically, and pro forma adjusted EPS of $1.41. Diagnostics revenue rose 11% organically, while Signals software declined 20% organically. Free cash flow was $184 million. Full-year organic growth guidance was raised to 4% to 5% and adjusted EPS to $5.30 to $5.40.

fool.com7 min
AUG 9
$RVTYMedAI 8/10

Revvity Q2 Earnings Call Highlights

Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.

finance.yahoo.com6 min
AUG 6
$RVTYMed

Revvity, Inc. Q2 2026 Earnings Call Summary

Revvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.

yahoo.com6 min
AUG 4
$RVTYMedAI 9/10

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

Revvity (RVTY) reported Q2 2026 adjusted EPS of $1.41, up 19.5% and above the $1.23 Zacks estimate. Revenue rose 1.3% to $729.7 million, beating $704.5 million. Pro forma revenues were $711.1 million. Diagnostics grew; Life Sciences declined. Revvity raised 2026 pro forma revenue to $2.83-$2.86B and EPS to $5.30-$5.40 and agreed to divest China Immunodiagnostics.

tradingview.com6 min